Home / Health / Tamil Nadu to Trial Japanese Dengue Vaccine
Tamil Nadu to Trial Japanese Dengue Vaccine
17 Oct
Summary
- Tamil Nadu will research Qdenga, a Japanese dengue vaccine, in Kadayanallur.
- The vaccine, approved in over 40 countries, offers 80-90% protection.
- A parallel study will test mosquito repellents for skin and vaporizers.
The Tamil Nadu government will conduct research in Kadayanallur to assess the effectiveness of Qdenga, a dengue vaccine developed by a Japanese firm. Health Minister K. G. Arunraj announced that this initiative aims to ensure no further deaths from dengue fever.
The vaccine, which has received prequalification from the World Health Organization (WHO), is reported to provide 80% to 90% protection against dengue when administered in two doses spaced three months apart. It has already been approved in over 40 countries, including Indonesia and Thailand, and is part of Brazil's national immunization schedule.
Following approval by the Central Drugs Standard Control Organisation (CDSCO) in July, Tamil Nadu has become the first state in India to introduce this dengue vaccine. Kadayanallur was selected due to its history of significant dengue outbreaks and associated fatalities.
In conjunction with the vaccine study, researchers will also investigate the efficacy of mosquito repellents applied to the skin and electric mosquito repellent vaporizers in protecting against mosquito bites within Kadayanallur.
